Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65

Executive Summary

On Nov. 7, Sacramento Superior Court Judge Ronald Robie temporarily set aside his day-earlier tentative ruling that would eliminate exemption for FDA-regulated drugs, cosmetics and medical devices from California's Propostion 65 cancer label-warning requirement. Judge Robie asked plaintiffs, the AFL-CIO, to submit a brief by Dec. 6 in support of the tentative ruling; defendants, the state, and intervenors have until Jan. 12 to respond. An early February hearing is expected.

On Nov. 7, Sacramento Superior Court Judge Ronald Robie temporarily set aside his day-earlier tentative ruling that would eliminate exemption for FDA-regulated drugs, cosmetics and medical devices from California's Propostion 65 cancer label-warning requirement. Judge Robie asked plaintiffs, the AFL-CIO, to submit a brief by Dec. 6 in support of the tentative ruling; defendants, the state, and intervenors have until Jan. 12 to respond. An early February hearing is expected.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel